MGTA News and Press, Magenta Therapeutics Inc. From 06/03/21

Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today announced that the company is scheduled to participate in a fireside chat at the Goldman Sachs 42nd Annual ...

ASCO is a very important cancer clinical research meeting. We identified 70 smid-cap cancer companies presenting updated clinical data at ASCO21. 13 companies' value increased by over 10% with ASCO21 info release thus far. PDSB is an early ASCO21 mover, with its HPV vaccine ca...

Magenta Therapeutics (MGTA) shares are up 15.7% in afternoon trading as B. Riley sees as much as $1.5B in peak sales from the company's stem cell transplant therapies in development.Analyst Kalpit Patel initiated a buy recommendation and a $21 price target (90% upside) on shares.Mag...

Recent IPO Agiliti named a buy at KeyBanc, BMOMedical equipment management firm Agiliti (AGTI), which started trading next month, has earned an overweight rating at KeyBanc and an outperform rating at BMO.KeyBanc has a $21 price target (~43% upside), while BMO's target is $18 (~22% upsid...

Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today announced that Jason Gardner, D.Phil., President and Chief Executive Officer, will participate in fireside ...

Magenta Therapeutics (MGTA) has announced a private placement of 9.6M shares priced at $9/share for expected gross proceeds of $86.4M.Institutional investors include Deep Track Capital, TCG X, Great Point Partners, OrbiMed, and Janus Henderson InvestorsThe closing is expected on May 14.Magent...

Magenta Therapeutics ([[MGTA]] +0.8%) announces positive preliminary results from its Phase 2 clinical trial of MGTA-145 plus plerixafor in patients with multiple myeloma.The investigator-initiated, 25-patient Phase 2 open-label clinical trial is designed to evaluate the ability of the drug c...

Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, announced that it has agreed to sell approximately 9,600,000 shares of its common stock to certain instituti...

- Preliminary results showed all patients with multiple myeloma (10/10) treated with MGTA-145 and plerixafor met the primary endpoint for stem cell mobilization and collection, and all transplanted patients (6/6) successfully engrafted as of the data cutoff date – - MGT...

Magenta Therapeutics (MGTA): Q1 GAAP EPS of -$0.36 beats by $0.04.Cash, cash equivalents and marketable securities of $132.29M.Press Release For further details see: Magenta Therapeutics EPS beats by $0.04